Genmab A/S (GMAB.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec12

Genmab Completes Acquisition of Merus N.V. for $97 per Share

06:35

Dec11

William Blair Analyst Reiterates Buy Rating on Genmab

22:27

Dec8

Genmab A/S Announces Positive Results for Epcoritamab in EPCORE CLL-1 Trial for Richter Transformation

21:30

JPMorgan Raises Genmab's Target Price to 2050 Danish Kroner

05:23

Dec7

Genmab A/S Announces EPKINLY Combined Treatment Study Results for Follicular Lymphoma

12:50

FDA Approves EPKINLY® for Follicular Lymphoma Treatment

12:50

Schedules & Filings

Schedules

Filings

Feb5

Earning Release(EST)

FY2025 Annual Earning Release

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 1.022 B, Net Income 401 M, EPS 0.646

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 925 M, Net Income 336 M, EPS 0.542

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More